# Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Study · id `cardio:ct-nct03684642` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03684642](<https://clinicaltrials.gov/study/NCT03684642>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03684642

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 908 participants.

## Technical summary

Registry record NCT03684642. Randomized; no masking; primary purpose treatment. Start 2018-09-26 (actual); primary completion 2020-10-13 (actual). Results posted on 2021-11-01.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 908 participants (enrolled count; ClinicalTrials.gov record NCT03684642, source copy `cardio:ctgov-nct03684642-2021-11-01`, retrieved 2026-10-26)
- Started: 2018-09-26 (actual) (ClinicalTrials.gov record NCT03684642, source copy `cardio:ctgov-nct03684642-2021-11-01`, retrieved 2026-10-26)
- Primary completion: 2020-10-13 (actual) (ClinicalTrials.gov record NCT03684642, source copy `cardio:ctgov-nct03684642-2021-11-01`, retrieved 2026-10-26)
- Completion: 2020-11-17 (actual) (ClinicalTrials.gov record NCT03684642, source copy `cardio:ctgov-nct03684642-2021-11-01`, retrieved 2026-10-26)
- Results first posted: 2021-11-01 (ClinicalTrials.gov record NCT03684642, source copy `cardio:ctgov-nct03684642-2021-11-01`, retrieved 2026-10-26)
- Countries: United States; Hungary; Poland; Ukraine (ClinicalTrials.gov record NCT03684642, source copy `cardio:ctgov-nct03684642-2021-11-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03684642-2021-11-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
- Acronym: AMPLITUDE-D
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Efpeglenatide
- Intervention (Drug): Dulaglutide
- Intervention (Drug): Background therapy Metformin
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Hanmi Pharmaceutical Company Limited
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 3292ea00ed3e1ecacc6aef3722344f88142d9b424319c2de91389b2e42a66d2c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
